Table 1.

Detailed information of patients with acute/hyperacute rejection accompanied with circulating AECAa

PatientGender/AgeUnderlying Renal DiseasePRA (HLA I/II; %)Diagnostic BiopsybBanff GradeC4dAECA TiterResponse to SteroidOther TreatmentOutcomeCurrent SCr (mo)
PretransplantationOn Rejection
1F/25CGN3/0NA0HAR+1:80ExcisedNoLost graftDialysis
2F/33CGN153.28/0.090HAR+1:80ExcisedNoLost graftDialysis
3M/39CGN103.60/0.657 dIII+1:10NoM+FControlledDied of pneumonia
4F/38CGN183.35/0.329 moIIA+1:10NoIA+M+FLost graftDialysis
5F/46Hypertension50/31c6.90/1.174 dIIA1:10YesNoReversed0.72 (78)
6M/41CGN176.95/0.957 dIIA1:20NoM+FLost graftDialysis
7M/38Polycystic kidney82.66/2.7455 dIIA+1:10YesNoReversedDialysis
8M/30CGN47cNA34 dIIB1:10NoATGLost graftDialysis
9M/44CGN16.723.2/0.352 dIIA1:10NoATGReversed1.24 (46)
10M/34CGN2.08/1.714.25/1.066 dIIB1:20YesM+FReversed0.98 (80)
11F/39CGN1.61/9.838.4/14.94 dIIB+1:40NoIA+F+MReversed0.77 (41)
12M/40Interstitial nephritis0.74/0.783.14/3.7232 dIIB+1:10NoPP+F+MLost graftDied of pneumonia
13F/51CGN3.22/0.429.74/0.458 dIII+1:80NoIA+F+MLost graftDialysis
14F/60CGN4.20/2.125.96/0.2845 dIIA1:20NoM+FReversed1.86 (36)
15M/45CGN0.86/6.602.73/7.867 dIIB1:20NoM+FReversed2.58 (38)
  • a AECA, anti-endothelial cell antibody; C, cyclosporin; CGN, primary chronic glomerulonephritis; F, FK506 (tacrolimus); IA, immunoadsorption; M, mycophenolate mofetil; P, prednisolone; PP, plasmapheresis; PRA, panel reactivity antibody, it was assessed by using a panel of cells from 50 phenotyped donors before 2000, <20% was considered negative, flow-PRA screening test was performed before transplantation since 2001, sera with >10% flow-PRA class I and/or II reactivity were considered anti-HLA antibody-positive; SCr, serum creatinine; Z, CD25mAb (zanapax, Roche).

  • b Measured by days after transplantation.

  • c Transplantation was performed when PRA were negative in these patients.